Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.

Humans COVID-19 / diagnosis SARS-CoV-2 / genetics Antibodies, Viral Biological Assay Immunoglobulin G

Antibody Binding antibody units COVID-19 Nucleocapsid RBD SARS-CoV-2 Serology Spike

Journal

Virology journal

ISSN: 1743-422X

Titre abrégé: Virol J

Pays: England

ID NLM: 101231645

Informations de publication

Date de publication:
01 09 2023

Historique:

received: 14 11 2022

accepted: 24 08 2023

medline: 5 9 2023

pubmed: 2 9 2023

entrez: 1 9 2023

Statut: epublish

Résumé

Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43-51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that.

Sections du résumé

BACKGROUND

METHODS

To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay.

RESULTS

In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43-51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly.

CONCLUSION

The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that.

Identifiants

DOI: 10.1186/s12985-023-02167-z PMID: 37658454 PMC: PMC10474769

pubmed: 37658454

doi: 10.1186/s12985-023-02167-z

pii: 10.1186/s12985-023-02167-z

pmc: PMC10474769

doi:

Substances chimiques

Antibodies, Viral 0

Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

200

Investigateurs

Emad Alamoudi (E)

Jared Anderson (J)

Valeria Baldassarre (V)

Maximilian Baumann (M)

Marc Becker (M)

Franziska Bednarski (F)

Marieke Behlen (M)

Olimbek Bemirayev (O)

Jessica Beyerl (J)

Patrick Bitzer (P)

Rebecca Böhnlein (R)

Isabel Brand (I)

Anna Brauer (A)

Vera Britz (V)

Franziska Bünz (F)

Friedrich Caroli (F)

Josephine Coleman (J)

Lorenzo Contento (L)

Alina Czwienzek (A)

Flora Deák (F)

Maximilian N Diefenbach (MN)

Jana Diekmannshemke (J)

Anna Do (A)

Gerhard Dobler (G)

Jürgen Durner (J)

Tabea Eser (T)

Ute Eberle (U)

Judith Eckstein (J)

Manuela Feyereisen (M)

Volker Fingerle (V)

Stefanie Fischer (S)

Felix Forster (F)

Günter Fröschl (G)

Christiane Fuchs (C)

Otto Geisenberger (O)

Mercè Garí (M)

Marius Gasser (M)

Sonja Gauder (S)

Raffaela Geier (R)

Kristina Gillig (K)

Keisha Gezgin (K)

Leonard Gilberg (L)

Kristina Gillig (K)

Philipp Girl (P)

Elias Golschan (E)

Vitus Grauvogl (V)

Jessica Michelle Guggenbuehl Noller (JMG)

Elena Maria Guglielmini (EM)

Pablo Gutierrez (P)

Anslem Haderer (A)

Celina Halfmann (C)

Marlene Hannes (M)

Lena Hartinger (L)

Timm Haselwarter (T)

Jan Hasenauer (J)

Alejandra Hernandez (A)

Luca Heller (L)

Arlett Heiber (A)

Matthias Herrmann (M)

Leah Hillari (L)

Stefan Hillmann (S)

Christian Hinske (C)

Janna Hoefflin (J)

Tim Hofberger (T)

Michael Höfinger (M)

Larissa Hofmann (L)

Kristina Huber (K)

Christian Janke (C)

Lilian Karger (L)

Ursula Kappl (U)

Antonia Keßler (A)

Zohaib Khan (Z)

Charlotte Kiani (C)

Isabel Klugherz (I)

Norah Kreider (N)

Johanna Kresin (J)

Arne Kroidl (A)

Pratik Kunder (P)

Magdalena Lang (M)

Clemens Lang (C)

Silvan Lange (S)

Ekaterina Lapteva (E)

Michael Laxy (M)

Ronan Le Gleut (R)

Reiner Leidl (R)

Leopold Liedl (L)

Felix Lindner (F)

Xhovana Lucaj (X)

Elisabeth Lucke (E)

Fabian Luppa (F)

Alexandra Sophie Nafziger (AS)

Alexander Maczka (A)

Petra Mang (P)

Paula Matcau (P)

Rebecca Mayrhofer (R)

Anna-Maria Mekota (AM)

Dafni Metaxa (D)

Emily Mohr (E)

Hannah Müller (H)

Katharina Müller (K)

Nathalia Nascimento (N)

Kasimir Niermeyer (K)

Sophia Nikolaides (S)

Ivan Noreña (I)

Leonie Pattard (L)

Michael Plank (M)

Claire Pleimelding (C)

Michel Pletschette (M)

Viona Poll (V)

Stephan Prückner (S)

Konstantin Pusl (K)

Peter Pütz (P)

Katja Radon (K)

Elba Raimúndez (E)

Julius Raschka (J)

Christina Reinkemeyer (C)

Camilla Rothe (C)

Viktoria Ruci (V)

Nicole Schäfer (N)

Yannik Schälte (Y)

Paul Schandelmaier (P)

Benedikt Schluse (B)

Annika Schneider (A)

Lara Schneider (L)

Sophie Schultz (S)

Mirjam Schunk (M)

Lars Schwettmann (L)

Josefin Sedlmeier (J)

Linda Sintu-Sempta (L)

Alba Soler (A)

Peter Sothmann (P)

Katharina Strobl (K)

Aida Strüber (A)

Laura Strüber (L)

Jeni Tang (J)

Fabian Theis (F)

Verena Thiel (V)

Eva Thumser (E)

Niklas Thur (N)

Sophie Thiesbrummel (S)

Julian Ullrich (J)

Vincent Vollmayr (V)

Emilia Von Lovenberg (E)

Jonathan Von Lovenberg (J)

Carsten Vos (C)

Julia Waibel (J)

Claudia Wallrauch (C)

Nikolas Weigl (N)

Roman Wölfl (R)

Julia Wolff (J)

Pia Wullinger (P)

Tobias Würfel (T)

Patrick Wustrow (P)

Sabine Zange (S)

Eleftheria Zeggini (E)

Thorbjörn Zimmer (T)

Thomas Zimmermann (T)

Lea Zuche (L)

Informations de copyright

Références

Viruses. 2020 Nov 27;12(12):

pubmed: 33260809

Lancet. 2021 Jan 9;397(10269):99-111

pubmed: 33306989

N Engl J Med. 2021 Apr 15;384(15):1412-1423

pubmed: 33626250

J Gen Virol. 2021 Oct;102(10):

pubmed: 34623233

Nat Med. 2021 Jul;27(7):1147-1148

pubmed: 34239135

Lancet. 2021 Apr 10;397(10282):1347-1348

pubmed: 33770519

Lancet Infect Dis. 2020 Aug;20(8):e192-e197

pubmed: 32539990

Infect Dis Ther. 2021 Jun 16;:1-14

pubmed: 34155471

N Engl J Med. 2021 Oct 14;385(16):1474-1484

pubmed: 34320281

Nat Med. 2021 Nov;27(11):2032-2040

pubmed: 34588689

N Engl J Med. 2021 Dec 9;385(24):e83

pubmed: 34614327

Lancet. 2022 Mar 5;399(10328):924-944

pubmed: 35202601

J Infect Dis. 2021 Feb 13;223(3):389-398

pubmed: 33140086

N Engl J Med. 2020 Oct 29;383(18):1724-1734

pubmed: 32871063

J Clin Virol. 2022 Jan;146:105052

pubmed: 34920374

Lancet. 2021 Jul 31;398(10298):385-387

pubmed: 34274038

Nat Med. 2020 Aug;26(8):1200-1204

pubmed: 32555424

Nat Commun. 2021 Nov 4;12(1):6379

pubmed: 34737312

N Engl J Med. 2021 Jun 10;384(23):2212-2218

pubmed: 33882219

Microorganisms. 2021 Mar 08;9(3):

pubmed: 33800489

Nat Med. 2020 Jun;26(6):845-848

pubmed: 32350462

Nat Microbiol. 2020 Dec;5(12):1598-1607

pubmed: 33106674

Sci Adv. 2021 Sep 03;7(36):eabj5365

pubmed: 34516917

Immunity. 2020 Nov 17;53(5):925-933.e4

pubmed: 33129373

N Engl J Med. 2021 Dec 9;385(24):e84

pubmed: 34614326

Sci Immunol. 2020 Dec 7;5(54):

pubmed: 33288645

Virology. 2022 Apr;569:37-43

pubmed: 35245784

N Engl J Med. 2021 Feb 11;384(6):533-540

pubmed: 33369366

Eur J Immunol. 2020 Dec;50(12):2025-2040

pubmed: 33084029

N Engl J Med. 2021 Feb 4;384(5):403-416

pubmed: 33378609

Lancet Respir Med. 2021 Jul;9(7):712-720

pubmed: 33865504

Science. 2021 Feb 5;371(6529):

pubmed: 33408181

Euro Surveill. 2021 Jul;26(30):

pubmed: 34328074

Signal Transduct Target Ther. 2020 Sep 2;5(1):180

pubmed: 32879307

N Engl J Med. 2020 Sep 10;383(11):1085-1087

pubmed: 32706954

Lancet. 2021 May 15;397(10287):1819-1829

pubmed: 33964222

J Infect. 2021 May;82(5):162-169

pubmed: 33766553

Nat Med. 2021 Feb;27(2):205-211

pubmed: 33469205

N Engl J Med. 2020 Dec 31;383(27):2603-2615

pubmed: 33301246

Nat Med. 2021 Sep;27(9):1525-1529

pubmed: 34262158

Nat Med. 2021 Dec;27(12):2136-2143

pubmed: 34728831